Related Experiment Video
Updated: Jun 11, 2025
Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
Published on: May 1, 2020
Second-Generation Cap Analogue Prodrugs for Targeting Aberrant Eukaryotic Translation Initiation Factor 4E (eIF4E)
Emilio L Cárdenas1, Rachel L O'Rourke1, Arya Menon1
1Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.
Abstract:
Melanoma is the deadliest form of skin cancer with a 5-year survival rate of less than 20%. While significant strides have been made in the field of kinase-targeted and immune-based therapies for melanoma, the development of resistance to these therapeutic agents has hindered the success of treatment. Drug-resistant melanoma is particularly reliant on enhanced cap-dependent translation to drive the production of oncoproteins that promote growth and survival. The m7GpppX cap-binding protein eukaryotic translation initiation factor 4E (eIF4E) is the rate-limiting factor of cap-dependent translation initiation, and its overexpression in melanoma tumors has been shown to drive resistance to BRAFV600E kinase-targeted inhibitors. These findings point to eIF4E-targeted therapies as a promising strategy to overcome drug resistance in melanoma. Herein, we build upon our previous work of developing cell-permeable cap analogue inhibitors to design second-generation cap analogues that inhibit eIF4E-mediated cap-dependent translation in drug-resistant melanoma cells.
Insights
Targeting eukaryotic translation initiation factor 4E (eIF4E) with novel cap analogues offers a promising strategy to overcome drug resistance in melanoma. These inhibitors block essential protein production, potentially improving treatment outcomes for advanced skin cancer.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Melanoma is a deadly skin cancer with poor survival rates, often developing resistance to current therapies.
- Drug-resistant melanoma relies on enhanced cap-dependent translation for oncoprotein production, promoting tumor growth.
- Eukaryotic translation initiation factor 4E (eIF4E), a key regulator of translation, is overexpressed in melanoma and linked to resistance against BRAF inhibitors.
Purpose of the Study:
- To develop novel therapeutic strategies targeting eIF4E to overcome drug resistance in melanoma.
- To design and synthesize second-generation cell-permeable cap analogues inhibiting eIF4E activity.
- To investigate the efficacy of these cap analogues in inhibiting eIF4E-mediated translation in drug-resistant melanoma cells.
Main Methods:
- Design and synthesis of second-generation cell-permeable cap analogues.
- In vitro assays to assess the inhibitory activity of cap analogues against eIF4E.
- Evaluation of cap analogue efficacy in drug-resistant melanoma cell models.
Main Results:
- Successful design and synthesis of novel cap analogue inhibitors.
- Demonstrated inhibition of eIF4E-mediated cap-dependent translation by the developed analogues.
- Potential for these compounds to reverse or overcome drug resistance in melanoma.
Conclusions:
- eIF4E-targeted therapies represent a viable strategy to combat drug resistance in melanoma.
- Second-generation cap analogues show promise in inhibiting aberrant translation driving melanoma progression.
- Further development of these inhibitors could lead to improved treatments for resistant melanoma.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...